{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:59:36Z","timestamp":1785275976973,"version":"3.55.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R21CA295917"],"award-info":[{"award-number":["1R21CA295917"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019329","name":"Emerson Collective LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-18-1-0483"],"award-info":[{"award-number":["W81XWH-18-1-0483"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.canlet.2025.218065","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:32:18Z","timestamp":1758943938000},"page":"218065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inhibition of DDX3 modulates immune signaling in aggressive breast cancers"],"prefix":"10.1016","volume":"634","author":[{"given":"Farhad","family":"Vesuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul T.","family":"Winnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marise Heerma","family":"van Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-3823","authenticated-orcid":false,"given":"Guus M.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3317-8855","authenticated-orcid":false,"given":"Natalie D.","family":"ter Hoeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-2745","authenticated-orcid":false,"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-1423","authenticated-orcid":false,"given":"Venu","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218065_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218065_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216907","article-title":"circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer","volume":"592","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib4","first-page":"19","article-title":"Spectural studies of ferrous deuteroporphyrin in organic solvents","volume":"241","author":"Brault","year":"1973","journal-title":"Nature: New biology"},{"key":"10.1016\/j.canlet.2025.218065_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13058-024-01925-3","article-title":"NF-kappaB associated markers of prognosis in early and metastatic triple negative breast cancer","volume":"26","author":"De La Cruz","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102246","article-title":"Prognostic prediction for inflammatory breast cancer patients using random survival forest modeling","volume":"52","author":"Jia","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2025.116288","article-title":"Inflammatory breast cancer response to modern neoadjuvant chemotherapy: tumor response and survival outcomes","volume":"243","author":"Mousa-Doust","year":"2025","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.canlet.2025.218065_bib8","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.31557\/APJCP.2023.24.10.3335","article-title":"Systematic review and meta-analysis of treatment effects on survival in patients with inflammatory breast cancer","volume":"24","author":"Bahrami","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.canlet.2025.218065_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16010124","article-title":"Pathologic complete response (pCR) and survival of women with inflammatory breast cancer (IBC): an analysis based on biologic subtypes and demographic characteristics","volume":"16","author":"Biswas","year":"2019","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.canlet.2025.218065_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12032-025-02846-7","article-title":"MicroRNA-driven organ-specific metastasis in triple-negative breast cancer: biogenesis, mechanisms, and therapeutic approaches","volume":"42","author":"Rathore","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5306\/wjco.v5.i2.125","article-title":"Systemic treatment strategies for triple-negative breast cancer","volume":"5","author":"Yadav","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-025-07746-y","article-title":"Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis","volume":"212","author":"Liutti","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2025.218065_bib13","article-title":"Real-World clinical outcomes of treatment with olaparib for BRCA1\/2 mutation-positive metastatic breast cancer in Japanese patients","volume":"16","author":"Tanaka","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.canlet.2025.218065_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447280","article-title":"Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218065_bib15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/2767-9764.CRC-23-0285","article-title":"Treatment response, tumor infiltrating lymphocytes and clinical outcomes in inflammatory breast cancer-treated with neoadjuvant systemic therapy","volume":"4","author":"De Schepper","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2025.218065_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000324032","article-title":"Fine-needle aspiration in suspected inflammatory breast cancer: case series with emphasis on approach to specimen adequacy","volume":"55","author":"Kumar","year":"2011","journal-title":"Acta Cytol."},{"key":"10.1016\/j.canlet.2025.218065_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.seminoncol.2007.11.010","article-title":"Defining the clinical diagnosis of inflammatory breast cancer","volume":"35","author":"Singletary","year":"2008","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cam4.48","article-title":"Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia","volume":"2","author":"Schairer","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2025.218065_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.ircmb.2023.10.006","article-title":"Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models","volume":"384","author":"Rypens","year":"2024","journal-title":"International review of cell and molecular biology"},{"key":"10.1016\/j.canlet.2025.218065_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"Lim","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib21","first-page":"787","article-title":"Inflammatory breast cancer: what to know about this unique, aggressive breast cancer","volume":"98","author":"Menta","year":"2018","journal-title":"Surg. Clin."},{"key":"10.1016\/j.canlet.2025.218065_bib22","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1684\/bdc.2014.2014","article-title":"[Systemic treatments of inflammatory breast cancer: an overview]","volume":"101","author":"Monneur","year":"2014","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib23","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/cncr.25168","article-title":"Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience","volume":"116","author":"Viens","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib25","doi-asserted-by":"crossref","first-page":"12417","DOI":"10.18632\/oncotarget.13778","article-title":"Developmental therapeutics for inflammatory breast cancer: biology and translational directions","volume":"8","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218065_bib26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10552-014-0395-1","article-title":"Racial\/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and end results data","volume":"25","author":"Schinkel","year":"2014","journal-title":"Cancer causes & control : CCC (Cancer Causes Control)"},{"key":"10.1016\/j.canlet.2025.218065_bib27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1245\/s10434-013-3439-y","article-title":"Incidence of inflammatory breast cancer in women, 1992-2009, United States","volume":"21","author":"Goldner","year":"2014","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-023-07018-7","article-title":"Racial disparities in treatment and outcomes between Non-Hispanic Black and Non-Hispanic white women with nonmetastatic inflammatory breast cancer","volume":"201","author":"Carbajal-Ochoa","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2025.218065_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12282-009-0126-8","article-title":"Therapeutic strategies for breast cancer based on histological type","volume":"16","author":"Akiyama","year":"2009","journal-title":"Breast Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib30","first-page":"265","article-title":"Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review","volume":"17","author":"Jie","year":"2025","journal-title":"Breast cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218065_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156075","article-title":"Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy","volume":"272","author":"Rejili","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2025.218065_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1471-2407-5-137","article-title":"Short- and long-term cause-specific survival of patients with inflammatory breast cancer","volume":"5","author":"Tai","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cncr.22927","article-title":"Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease","volume":"110","author":"Cristofanilli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116254","article-title":"Non-oncogene dependencies: novel opportunities for cancer therapy","volume":"228","author":"Di Marco","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2025.218065_bib36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cell.2007.09.007","article-title":"Non-oncogene addiction and the stress phenotype of cancer cells","volume":"130","author":"Solimini","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218065_bib37","series-title":"Effect of anti-DR5 and Chemotherapy on Basal-like Breast Cancer","author":"Oliver","year":"2011"},{"key":"10.1016\/j.canlet.2025.218065_bib38","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1038\/onc.2008.33","article-title":"Oncogenic role of DDX3 in breast cancer biogenesis","volume":"27","author":"Botlagunta","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218065_bib39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.bbrc.2004.01.151","article-title":"Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma","volume":"315","author":"Huang","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2025.218065_bib40","article-title":"USP7 imparts partial EMT state in colorectal cancer by stabilizing the RNA helicase DDX3X and augmenting Wnt\/beta-catenin signaling, Biochimica et biophysica acta","volume":"1870","author":"Basu","year":"2023","journal-title":"Molecular cell research"},{"key":"10.1016\/j.canlet.2025.218065_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27207010","article-title":"DDX3 Upregulates Hydrogen peroxide-induced melanogenesis in Sk-Mel-2 human melanoma cells","volume":"27","author":"Eom","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2025.218065_bib42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/2211-5463.13920","article-title":"DDX3 participates in miRNA biogenesis and RNA interference through translational control of PACT and interaction with AGO2","volume":"15","author":"Lai","year":"2025","journal-title":"FEBS open bio"},{"key":"10.1016\/j.canlet.2025.218065_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106157","article-title":"Corrigendum to \"TRIM58 inactivates p53\/p21 to promote chemoresistance via ubiquitination of DDX3 in breast cancer\"","volume":"144","author":"Wang","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218065_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216426","article-title":"ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade","volume":"577","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41389-024-00509-2","article-title":"DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression","volume":"13","author":"Zhao","year":"2024","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2025.218065_bib46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.15252\/emmm.201404368","article-title":"Targeting DDX3 with a small molecule inhibitor for lung cancer therapy","volume":"7","author":"Bol","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2025.218065_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1021\/ml100281b","article-title":"Novel, broad spectrum anticancer agents containing the tricyclic 5:7:5-fused diimidazodiazepine ring system","volume":"2","author":"Kondaskar","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib48","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1158\/0008-5472.CAN-16-0440","article-title":"RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3","volume":"76","author":"Xie","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1099\/vir.0.015909-0","article-title":"Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein","volume":"91","author":"Angus","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.canlet.2025.218065_bib50","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1158\/0008-5472.CAN-05-0712","article-title":"Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer","volume":"65","author":"Mironchik","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib51","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1634\/theoncologist.2011-0196","article-title":"Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer","volume":"16","author":"Li","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.218065_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3579","article-title":"Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers","volume":"15","author":"Masuda","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10585-016-9832-8","article-title":"The prognostic effect of DDX3 upregulation in distant breast cancer metastases","volume":"34","author":"Heerma van Voss","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2025.218065_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132710","article-title":"Inflammation mediated metastasis: immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218065_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13058-015-0549-4","article-title":"Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model","volume":"17","author":"Lacerda","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-013-2600-4","article-title":"Inflammatory breast cancer (IBC): clues for targeted therapies","volume":"140","author":"Fernandez","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2025.218065_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-9966-33-47","article-title":"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models","volume":"33","author":"Mu","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib58","doi-asserted-by":"crossref","first-page":"33197","DOI":"10.18632\/oncotarget.16593","article-title":"DEAD)-box RNA helicase 3 modulates NF-\u0152\u222bB signal pathway by controlling the phosphorylation of PP2A-C subunit","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218065_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13058-019-1140-1","article-title":"Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer","volume":"21","author":"Provance","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib60","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex cytokine network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.1231499","article-title":"RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in wnt-beta-catenin signaling","volume":"339","author":"Cruciat","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218065_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1476-4598-8-43","article-title":"Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers","volume":"8","author":"Cheung","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib63","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2147\/OTT.S33374","article-title":"Survivin - biology and potential as a therapeutic target in oncology","volume":"6","author":"Cheung","year":"2013","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2025.218065_bib64","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1073\/pnas.1106245108","article-title":"DEAD-box RNA helicase Belle\/DDX3 and the RNA interference pathway promote mitotic chromosome segregation","volume":"108","author":"Pek","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218065_bib65","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.1038\/s41598-017-09779-w","article-title":"DDX3 localizes to the centrosome and prevents multipolar mitosis by epigenetically and translationally modulating p53 expression","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib66","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.3892\/mmr.2015.4389","article-title":"Gene expression profile analysis of ventilator-associated pneumonia","volume":"12","author":"Xu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib67","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/0284186X.2014.932006","article-title":"Reprogramming of tumor metabolism by targeting mitochondria improves tumor response to irradiation","volume":"54","author":"Bol","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canlet.2025.218065_bib68","article-title":"Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer","volume":"12","author":"Schreier","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","article-title":"Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy","volume":"29","author":"Renner","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218065_bib72","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased Tumor glycolysis characterizes immune resistance to adoptive T cell therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2025.218065_bib73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2025.218065_bib74","article-title":"Targeting the organelle for radiosensitization in cancer radiotherapy","volume":"19","author":"Sun","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.canlet.2025.218065_bib75","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.mt.6300310","article-title":"Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation","volume":"15","author":"Chen","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2025.218065_bib76","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-Omics characterization of the 4T1 Murine mammary Gland tumor model","volume":"10","author":"Schr\u221a\u2202rs","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib77","article-title":"In situ vaccination with mitochondria-targeting immunogenic death inducer elicits CD8(+) T cell-dependent antitumor immunity to boost tumor immunotherapy","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2025.218065_bib78","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/OTT.S160911","article-title":"High neutrophil to lymphocyte ratio and decreased CD69(+)NK cells represent a phenotype of high risk in early-stage breast cancer patients","volume":"11","author":"Mando","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2025.218065_bib79","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3892\/ol.2017.6305","article-title":"Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer","volume":"14","author":"Gonda","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib80","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1593\/neo.06304","article-title":"Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer","volume":"8","author":"Winnard","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2025.218065_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2020.08.014","article-title":"Update on systemic treatment for newly diagnosed inflammatory breast cancer","volume":"29","author":"Chainitikun","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2025.218065_bib82","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-023-00555-w","article-title":"Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer","volume":"9","author":"Garrido-Castro","year":"2023","journal-title":"NPJ breast cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib83","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.canlet.2017.09.033","article-title":"Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells","volume":"411","author":"Oladapo","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3835(94)03684-B","article-title":"Primary chemotherapy for early and advanced breast cancer","volume":"90","author":"Hortobagyi","year":"1995","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13063-025-08726-9","article-title":"A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)","volume":"26","author":"Arora","year":"2025","journal-title":"Trials"},{"key":"10.1016\/j.canlet.2025.218065_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251327992","article-title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"17","author":"Schmid","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clbc.2021.05.009","article-title":"A phase II Study evaluating the safety and efficacy of sunitinib malate in combination with weekly paclitaxel followed by Doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer","volume":"22","author":"Symonds","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib88","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1593\/neo.91084","article-title":"Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression","volume":"11","author":"Vesuna","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2025.218065_bib89","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/SCR:1:3:207","article-title":"Stem cells in mammary development and carcinogenesis: implications for prevention and treatment","volume":"1","author":"Dontu","year":"2005","journal-title":"Stem Cell Rev."},{"key":"10.1016\/j.canlet.2025.218065_bib90","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr1982","article-title":"Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy","volume":"10","author":"Fillmore","year":"2008","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.023","article-title":"Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells","volume":"394","author":"Burnett","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.11.026","article-title":"High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha","volume":"333","author":"Kim","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib93","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14796694.2025.2461443","article-title":"An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer","volume":"21","author":"Jan","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167899","article-title":"Characterization and targeting of chemoresistant triple-negative breast cancer subtypes using amino-pyridine compounds","volume":"1871","author":"Ruiz-Martinez","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2025.218065_bib95","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2020.07.053","article-title":"RNA polymerase II-Associated factor 1 regulates stem cell features of pancreatic cancer cells, independently of the PAF1 complex, via interactions with PHF5A and DDX3","volume":"159","author":"Karmakar","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.218065_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1148936","article-title":"The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma","volume":"13","author":"Lacroix","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib97","first-page":"233","article-title":"DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m(6)A-demethylation of FOXM1 and NANOG, Apoptosis","volume":"25","author":"Shriwas","year":"2020","journal-title":"an international journal on programmed cell death"},{"key":"10.1016\/j.canlet.2025.218065_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18632\/genesandcancer.187","article-title":"Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation","volume":"10","author":"Kerr","year":"2019","journal-title":"Genes Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib99","article-title":"DEAD-Box helicase 3 modulates the non-coding RNA pool in ribonucleoprotein condensates during stress granule Formation","volume":"11","author":"Korunova","year":"2025","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.canlet.2025.218065_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216508","article-title":"A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer","volume":"581","author":"Wu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib101","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2886","article-title":"NF-\u0152\u222bB, stem cells and breast cancer: the links get stronger","volume":"13","author":"Shostak","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0105-2896.2006.00375.x","article-title":"Circuitry of nuclear factor kappaB signaling","volume":"210","author":"Hoffmann","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2025.218065_bib103","first-page":"351","article-title":"Inflammatory breast cancer: the disease, the biology, the treatment","volume":"60","author":"Robertson","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218065_bib104","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.bjc.6603967","article-title":"Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis","volume":"97","author":"Van Laere","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib105","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.21037\/tcr.2019.03.24","article-title":"Pathological and molecular characteristics of inflammatory breast cancer","volume":"8","author":"Di Bonito","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib106","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jare.2013.06.004","article-title":"Inflammatory breast cancer: new factors contribute to disease etiology: a review","volume":"5","author":"Mohamed","year":"2014","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2025.218065_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clbc.2015.11.006","article-title":"Hyperactivated mTOR and JAK2\/STAT3 pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after neoadjuvant chemotherapy","volume":"16","author":"Jhaveri","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2025.218065_bib108","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/bcr997","article-title":"Update on inflammatory breast cancer","volume":"7","author":"Lerebours","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/bcr89","article-title":"Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants","volume":"2","author":"Kleer","year":"2000","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib111","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1158\/1078-0432.CCR-04-0306","article-title":"Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature","volume":"10","author":"Bi\u221a\u00aeche","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib112","doi-asserted-by":"crossref","first-page":"28312","DOI":"10.18632\/oncotarget.4873","article-title":"Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer","volume":"6","author":"Heerma van Voss","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218065_bib113","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tranon.2018.09.002","article-title":"Targeting DDX3 in medulloblastoma using the small molecule Inhibitor RK-33","volume":"12","author":"Tantravedi","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib114","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1073\/pnas.0600065103","article-title":"Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a notch-dependent mechanism","volume":"103","author":"Ayyanan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218065_bib115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/bcr1021","article-title":"Mammary stem cells, self-renewal pathways, and carcinogenesis","volume":"7","author":"Liu","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2025.218065_bib116","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1073\/pnas.0606599104","article-title":"WNT\/beta-catenin mediates radiation resistance of mouse mammary progenitor cells","volume":"104","author":"Woodward","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218065_bib117","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5521","article-title":"ABCG8-mediated sterol efflux increases cancer cell progression via the LRP6\/Wnt\/beta-catenin signaling pathway in radiotherapy-resistant MDA-MB-231 triple-negative breast cancer cells","volume":"55","author":"Ko","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2025.218065_bib118","doi-asserted-by":"crossref","DOI":"10.4014\/jmb.2503.03002","article-title":"Bufalin suppresses triple-negative breast cancer stem cell growth by inhibiting the Wnt\/beta-Catenin signaling pathway","volume":"35","author":"Park","year":"2025","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.canlet.2025.218065_bib119","article-title":"SIAH2-AS1 stimulates breast cancer cell proliferation and migration via the Wnt\/beta-catenin signaling pathway","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41698-025-01029-x","article-title":"Pan-cancer, multi-omic correlates of survival transcending tumor lineage across 11,019 patients reveal targets and pathways","volume":"9","author":"Zhang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104994","article-title":"Targeting host DEAD-box RNA helicase DDX3X for treating viral infections","volume":"185","author":"Winnard","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.canlet.2025.218065_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108925","article-title":"RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in ewing sarcoma","volume":"27","author":"Randolph","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2025.218065_bib123","article-title":"DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1","volume":"43","author":"Chen","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/onc.2017.308","article-title":"Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment","volume":"37","author":"Heerma van Voss","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218065_bib125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jmb.2011.12.024","article-title":"Dissection of the network of interactions that links RNA processing with glycolysis in the Bacillus subtilis degradosome","volume":"416","author":"Newman","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2025.218065_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010694","article-title":"The DEAD-box RNA helicase Dhx15 controls glycolysis and arbovirus replication in Aedes aegypti mosquito cells","volume":"18","author":"Rosendo Machado","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.canlet.2025.218065_bib127","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1111\/cas.14601","article-title":"Targeting RNA helicase DHX33 blocks Ras-driven lung tumorigenesis in vivo","volume":"111","author":"Wang","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2025.218065_bib128","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.canlet.2020.08.044","article-title":"Differentiated cancer cell-originated lactate promotes the self-renewal of cancer stem cells in patient-derived colorectal cancer organoids","volume":"493","author":"Zhao","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib129","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218065_bib130","first-page":"453","article-title":"Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release","volume":"39","author":"Goetze","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib131","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.218065_bib132","article-title":"Tumor microenvironment lactate: is it a cancer progression marker, immunosuppressant, and therapeutic target?","volume":"30","author":"Kim","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2025.218065_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.598626","article-title":"Lactate metabolism and immune modulation in breast cancer: a focused review on triple negative breast tumors","volume":"10","author":"Naik","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib134","article-title":"Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer","volume":"12","author":"Schreier","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218065_bib135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/excr.2002.5508","article-title":"Lactate stimulates fibroblast expression of hyaluronan and CD44: the warburg effect revisited","volume":"276","author":"Stern","year":"2002","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2025.218065_bib136","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/ar.24147","article-title":"The CD147-HYALURONAN axis in cancer","volume":"303","author":"Toole","year":"2020","journal-title":"Anat. Rec."},{"key":"10.1016\/j.canlet.2025.218065_bib137","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/onc.2017.308","article-title":"Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment","volume":"37","author":"Heerma van Voss","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218065_bib138","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2174\/1389201011314030010","article-title":"Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors","volume":"14","author":"Hahn","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.canlet.2025.218065_bib139","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/1873-3468.12711","article-title":"mTORC1 and mTORC2 as regulators of cell metabolism in immunity","volume":"591","author":"Linke","year":"2017","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2025.218065_bib140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ni.3704","article-title":"Mitochondria are the powerhouses of immunity","volume":"18","author":"Mills","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2025.218065_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/srep39303","article-title":"Surfactin inducing mitochondria-dependent ROS to activate MAPKs, NF-kappaB and inflammasomes in macrophages for adjuvant activity","volume":"6","author":"Gan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218065_bib142","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s12272-016-0827-4","article-title":"Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance","volume":"39","author":"Yu","year":"2016","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.canlet.2025.218065_bib143","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1242\/jeb.123.1.159","article-title":"Spontaneous and elicited bag cell discharges in gonadectomized aplysia","volume":"123","author":"Ferguson","year":"1986","journal-title":"J. Exp. Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:18:13Z","timestamp":1785273493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525006378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":143,"alternative-id":["S0304383525006378"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218065","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of DDX3 modulates immune signaling in aggressive breast cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218065"}}